Navigation Links
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF(TM) met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. Unlike fixed dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive patient self-titrated delivery system designed to enable patients to identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.

The trial evaluated the SPRID4 for AeroLEF(TM) compared with placebo for the treatment of the first pain episode. SPRID4 is a summary of the combined changes in pain relief and in pain intensity that patients report over the first 4 hours following initiation of dosing. The trial also examined a number of secondary endpoints including various measurements of pain relief, pain intensity, as well as onset and duration of analgesia, that are commonly used as indicators of efficacy for acute pain products. Various safety measurements were also examined.

"These results continue to demonstrate the unique potential for AeroLEF(TM) to be further developed into a valuable product for pain management across a broad range of indications, which could include post-operative pain, medical emergency pain and breakthrough pain," said David All
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
(Date:8/27/2014)... Aug. 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ... Drug Administration (FDA) to initiate a Phase 1/2a clinical ... cervical spinal cord injury.  The approved trial follows the ... the product, and is designed to assess safety and ... complete cervical spinal cord injuries, the first targeted indication ...
Breaking Medicine Technology:Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive ... company's drug, IPLEX(TM), in,patients with myotonic muscular dystrophy ... conducted at,the University of Rochester School of Medicine ... doses of IPLEX up to 1,mg/kg/day in six ...
... Ferret Study to be Part of Data Package ... 2007 /PRNewswire-FirstCall/ -- Novavax,Inc. said today that it ... challenge to ferrets inoculated with its pandemic,influenza vaccine, ... on,schedule later this year. , In the study, ...
Cached Medicine Technology:Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 3
(Date:8/27/2014)... Amy Norton HealthDay Reporter , ... part in clinical trials of new heart disease treatments are ... new study confirms. Experts said the findings, which appear ... Association , aren,t surprising -- but they are troubling. ... more select patient population that is not fully representative of ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... spending for commercially insured individuals is due primarily to ... use, according to a new study led by researchers ... Practice, published in the August issue of the ... increasing concern that consolidation in the health care marketplace ... ultimately, consumers," said Carrie Colla, PhD, assistant professor at ...
(Date:8/27/2014)... 27, 2014 CarePoint Health is ... Hoboken Pediatrics has joined our network, CarePoint Health ... Dr. Piotr Oko, Dr. Yanina Meshko and Dr. ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
(Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
Breaking Medicine News(10 mins):Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:Tracking spending among the commercially insured 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2
... could deter more than 100,000 Californians from enrolling in ... today by the California Pan-Ethnic Health Network, the UCLA ... Center for Labor Research and Education. ... that estimates the likely enrollment in health care reform ...
... , WEDNESDAY, Feb. 29 (HealthDay News) -- Federal ... helped provide guidance on whether it,s safe or effective for ... The Institute of Medicine (IOM) report noted, however, ... drugs in newborns or the long-term effects of drugs on ...
... people with diabetes could be adapted into a home DNA ... and bacteria in human body fluids, in food and in ... report on this adaptation of the ubiquitous personal glucose monitor, ... journal Analytical Chemistry . Yi Lu and Yu ...
... (FDA) announced it is revising safety information on the labels ... class of drugs that work in the liver to prevent ... at lowering the LDL (bad) cholesterol, but also have modest ... cholesterol. High cholesterol is a risk factor for ...
... HealthDay Reporter , TUESDAY, Feb. 28 (HealthDay News) ... emergency room with fevers are making the right decision, ... not be generalized, and therefore not approached, as a ... Dr. Yvette van Ierland, from the department of pediatrics ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Taking the ... fetus and lead to poorer motor control in infants, a ... their substance-abuse history before and during pregnancy. The women were ... Infancy Study, which looks at recreational drug use among pregnant ...
Cached Medicine News:Health News:Study: Over 100,000 Californians likely to miss out on health care due to language barriers 2Health News:Efforts to Improve Research on Kids' Drugs Paying Off: Report 2Health News:American Heart Association comment: FDA announces safety changes on labeling for some statins 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: